Faina Barer

1.6k total citations
26 papers, 1.4k citations indexed

About

Faina Barer is a scholar working on Physiology, Oncology and Cancer Research. According to data from OpenAlex, Faina Barer has authored 26 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 10 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Faina Barer's work include Adenosine and Purinergic Signaling (20 papers), Peptidase Inhibition and Analysis (9 papers) and NF-κB Signaling Pathways (5 papers). Faina Barer is often cited by papers focused on Adenosine and Purinergic Signaling (20 papers), Peptidase Inhibition and Analysis (9 papers) and NF-κB Signaling Pathways (5 papers). Faina Barer collaborates with scholars based in Israel, United States and Netherlands. Faina Barer's co-authors include Pnina Fishman, Sara Bar‐Yehuda, Lea Madi, Gil Ohana, Avivit Ochaion, Shira Cohen, S. Bar‐Yehuda, Lea Rath‐Wolfson, Luis Del Valle and Asha S. Multani and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Faina Barer

23 papers receiving 1.3k citations

Peers

Faina Barer

PHYSI

MB

ONCOL

IMMUN

OC

Avivit Ochaion Israel

Sara Bar‐Yehuda Israel

Stephen MacLennan Italy

Xiaofeng Sun China

Masaharu Terashima Japan

Jinfeng Zhu China

Diane Bouïs United States

Anaïs Brassier France

Letícia Scussel Bergamin Brazil

Gilles Alberici France

Avivit Ochaion Israel

Faina Barer

866 ×0.8

PHYSI

490 ×0.8

MB

240 ×0.8

ONCOL

187 ×0.9

IMMUN

137 ×0.7

OC

Citations per year, relative to Faina Barer Faina Barer (= 1×) peers Avivit Ochaion

Countries citing papers authored by Faina Barer

Since Specialization

Citations

This map shows the geographic impact of Faina Barer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faina Barer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faina Barer more than expected).

Fields of papers citing papers by Faina Barer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Faina Barer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faina Barer. The network helps show where Faina Barer may publish in the future.

Co-authorship network of co-authors of Faina Barer

This figure shows the co-authorship network connecting the top 25 collaborators of Faina Barer. A scholar is included among the top collaborators of Faina Barer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Faina Barer. Faina Barer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Cohen, Shira, et al.. (2015). THU0064 The A3 Adenosine Receptor (A3AR): Therapeutic Target and Predictive Biological Marker in Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 74. 215–215. 2 indexed citations

2.

Cohen, Shira, Salomon M. Stemmer, Avivit Ochaion, et al.. (2010). CF102 an A₃ adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver. Journal of Cellular Physiology. 226(9). 2438–2447. 73 indexed citations

3.

Ochaion, Avivit, S. Bar‐Yehuda, Shira Cohen, et al.. (2009). The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease. Cellular Immunology. 258(2). 115–122. 104 indexed citations

4.

Bar‐Yehuda, S., Lea Rath‐Wolfson, Luis Del Valle, et al.. (2009). Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis & Rheumatism. 60(10). 3061–3071. 107 indexed citations

5.

Stemmer, Salomon M., Lea Madi, David Castel, et al.. (2008). CF102 an A3 adenosine receptor agonist induces in vivo apoptosis of Hepatocellular carcinoma. Cancer Research. 68. 5712–5712.

6.

Ochaion, Avivit, S. Bar‐Yehuda, Shira Cohen, et al.. (2008). The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochemical Pharmacology. 76(4). 482–494. 60 indexed citations

7.

Stemmer, Salomon M., Lea Madi, David Castel, et al.. (2008). Effect of CF102 on growth suppression and apoptosis in an orthotopic model of hepatocellular carcinoma. Journal of Clinical Oncology. 26(15_suppl). 22113–22113. 1 indexed citations

8.

Madi, Lea, et al.. (2007). Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level.. PubMed. 34(1). 20–6. 64 indexed citations

9.

Ochaion, Avivit, Sara Bar‐Yehuda, Luis Del Valle, et al.. (2006). Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3adenosine receptor expression. Arthritis Research & Therapy. 8(6). R169–R169. 51 indexed citations

10.

Stemmer, Salomon M., et al.. (2006). A₃ adenosine receptor is highly expressed in hepatocellular carcinoma: A new therapeutic target. Journal of Clinical Oncology. 24(18_suppl). 13164–13164.

11.

Fishman, Pnina, Sara Bar‐Yehuda, Gil Ohana, et al.. (2003). An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB. Oncogene. 23(14). 2465–2471. 85 indexed citations

12.

Madi, Lea, et al.. (2003). A3 Adenosine Receptor Activation in Melanoma Cells. Journal of Biological Chemistry. 278(43). 42121–42130. 80 indexed citations

13.

Fishman, Pnina, Lea Madi, Sara Bar‐Yehuda, et al.. (2002). Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene. 21(25). 4060–4064. 88 indexed citations

14.

Fishman, Pnina, Sara Bar‐Yehuda, Faina Barer, et al.. (2001). The A3 Adenosine Receptor as a New Target for Cancer Therapy and Chemoprotection. Experimental Cell Research. 269(2). 230–236. 105 indexed citations

15.

Bar‐Yehuda, Sara, et al.. (2001). Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists. Neoplasia. 3(2). 125–131. 72 indexed citations

16.

Fishman, Pnina, S. Bar‐Yehuda, Gil Ohana, et al.. (2000). Adenosine acts as an inhibitor of lymphoma cell growth. European Journal of Cancer. 36(11). 1452–1458. 81 indexed citations

17.

Fishman, Pnina, et al.. (2000). Adenosine acts as a chemoprotective agent by stimulating G-CSF production: A role for A1 and A3 adenosine receptors. Journal of Cellular Physiology. 183(3). 393–398. 50 indexed citations

18.

Ohana, Gil, Sara Bar‐Yehuda, Faina Barer, & Pnina Fishman. (2000). Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor. Journal of Cellular Physiology. 186(1). 19–23. 108 indexed citations

19.

Fishman, Pnina, et al.. (2000). Adenosine acts as a chemoprotective agent by stimulating G-CSF production: A role for A1 and A3 adenosine receptors. Journal of Cellular Physiology. 183(3). 393–393. 4 indexed citations

20.

Bar‐Yehuda, Sara, et al.. (1999). Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice. Clinical & Experimental Metastasis. 17(6). 531–535. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact